

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4734		SERIAL NO.: 10/066,951		
				APPLICANT: BIGGADIKE, et. al.				
				FILING DATE: 02/04/2002		GROUP 1616		
U.S. PATENT DOCUMENTS								
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate		
BB	A1	3,067,197	12/04/62	Agnello et al.				
	A2	3,639,434	02/01/72	Oxley et al.				
	A3	3,828,080	08/06/74	May et al.				
	A4	3,856,828	12/24/74	Phillips et al.				
	A5	3,981,894	09/21/76	Phillips et al.				
	A6	3,989,686	11/02/76	Phillips et al.				
	A7	4,093,721	06/06/78	Phillips et al.				
	A8	4,187,301	02/05/80	Edwards				
	A9	4,188,385	02/12/80	Edwards				
	A10	4,198,403	04/15/80	Alvarez				
	A11	4,261,984	04/14/81	Alvarez				
	A12	4,263,289	04/21/81	Edwards				
	A13	4,267,173	05/12/81	Draper				
	A14	4,285,937	08/25/81	Kalvoda				
	A15	4,310,466	01/12/82	Edwards				
	A16	4,377,575	03/22/83	Phillips et al.				
	A17	4,607,028	08/19/86	Schmidlin				
	A18	4,710,495	12/01/87	Bodor				
	A19	4,861,765	08/29/89	Jouveinal				
	A20	4,992,474	02/12/91	Skidmore et al.				
	A21	4,994,439	02/19/91	Longnecker et al.				
	A22	4,996,335	02/26/91	Bodor				
	A23	5,250,293	10/24/86	Gleich				
	A24	5,420,120	05/30/95	Boltralik				
	A25	5,707,984	01/13/98	Tjoeng et al.				
	A26	5,849,265	12/98	Li-Bovet et al.				
	A27	5,919,776	11/13/02	Hagmann et al.				
	BB	A28	5,972,920	10/26/99	Seidel			
		A29	5,981,517	11/09/99	Bodor			
Continued on page								
FOREIGN PATENT DOCUMENTS								
Document Number	Publication Date	Country	Class	Subclass	Translation Yes No			
Continued on page								
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)								
Continued on page								
EXAMINER <i>Radio</i>				DATE CONSIDERED 1/12/04				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4734		SERIAL NO.: 10/066,951	
				APPLICANT: BIGGADIKE, et. al.			
				FILING DATE: 02/04/2002		GROUP 1616	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continued on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
<i>BB</i>	B1	92/14472	09/03/92	PCT	 	 	
	B2	94/21229	09/29/94	PCT	 	 	
	B3	96/19199	06/27/96	PCT	 	 	
	B4	97/05136	02/13/97	PCT	 	 	
	B5	97/15298	05/01/97	PCT	 	 	
	B6	97/24365	07/10/97	PCT	 	 	
	B7	98/34596	08/13/98	PCT	 	 	
	B8	98/43630	10/08/98	PCT	 	 	
	B9	99/01467	01/14/99	PCT	 	 	
	B10	00/38811	07/06/00	PCT	 	 	
	B11	00/57401	08/15/00	PCT	 	 	
	B12	01/04118	01/18/01	PCT	 	 	
	B13	01/15744	03/08/01	PCT	 	 	
	B14	01/20331	03/22/01	PCT	 	 	
	B15	01/62722	08/30/01	PCT	 	 	
	B16	01/78736	10/25/01	PCT	 	 	
	B17	01/78739	10/25/01	PCT	 	 	
	B18	01/78741	10/25/01	PCT	 	 	
	B19	02/00199	01/03/02	PCT	 	 	
	B20	02/00679	01/03/02	PCT	 	 	
	B21	02/008243	01/31/02	PCT	 	 	
	B22	02/013868	02/21/02	PCT	 	 	
	B23	02/26723	04/04/02	PCT	 	 	
	<i>BB</i>	B24	02/070490	09/12/02	PCT	 	
B25		02/076933	10/03/02	PCT	 	 	
Continued on page 3							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continued on page							
EXAMINER <i>Radio</i>					DATE CONSIDERED <i>1/13/04</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4734		SERIAL NO.: 10/066,951	
				APPLICANT: BIGGADIKE, et. al.			
				FILING DATE: 02/04/2002		GROUP 1616	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continued on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
BB	B25	02/085296	10/31/02	PCT			
	B26	02/088167	11/07/02	PCT			
	B27	02/100879	12/19/02	PCT			
	B28	03/013427	02/20/03	PCT			
	B29	03/033000	04/24/03	PCT			
	B30	03/035668	05/01/03	PCT			
	B31	03/040691	05/15/03	PCT			
	B32	03/042229	05/22/03	PCT			
	B33	03/042230	05/22/03	PCT			
	B34	0004773	10/17/79	EP			
	B35	0057401	08/11/82	EP			
	B36	0135476	03/27/85	EP			YES US4607028
	B37	0179583	04/30/86	EP			
	B38	0416951	03/13/91	EP			
	B39	0418716	03/27/91	EP			YES WO9104252
	B40	0521455	01/07/93	EP			
	B41	0640616	03/01/95	EP			YES US5608093
	B42	0646593	04/05/95	EP			ABSTRACT
	B43	2336693	02/06/75	DE			NO
	B44	2538569	03/03/77	DE			NO
B45	1384372	02/19/75	GB				
B46	1438940	06/09/76	GB				
B47	1517278	07/12/78	GB				
B48	2079755	01/27/82	GB				
B49	2140800	12/05/84	GB				
B50	04208267	07/29/92	JP			ABSTRACT	
B51	580494	10/24/86	FR			YES US4948583	
BB	B52	109656	02/22/98	IL			
	B53	872389	04/02/87	ZA			
Continued on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continued on page							
EXAMINER <i>Padio</i>					DATE CONSIDERED <i>11/12/04</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4734		SERIAL NO.: 10/066,951	
				APPLICANT: BIGGADIKE, et. al.			
				FILING DATE: 02/04/2002		GROUP 1616	

U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continued on page							

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
Continued on page							

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)		
BB	C15	Harold S. Nelson et al. "Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast," J. Allergy Clin. Immunol., Vol. 106, No. 6, December 2000, pp. 1088-1095
	C16	Gunnar Johansson et al., "Comparison of Salmeterol/Fluticasone Propionate Combination With Budesonide in Patients With Mild-to-Moderate Asthma" Clin. Drug Invest. Vol. 21, No. 9, 2001, pp. 633-642.
	C17	Bertil Pettersson et al., Re-evaluation of the classical Mycoplasma lipophilum cluster (Weisburg et al. 1989) and description of two new clusters in the hominis group based on 16S rDNA sequences," Int'l Journal of Systematic & Evolutionary Microbiology (2001) Vol. 51, pp. 633-643
	C18	Sarah A. Lewis et al., "Association of specific allergen sensitization with socioeconomic factors and allergic disease in a population of Boston women", J. Allergy Clin. Immunol., Vol. 107, No. 4, April 2001, pp. 615-622
	C19	Katherine A. Lyseng-Williamson et al., "Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease," Am. J. Respir. Med. Vol. 1, No. 4, 2002, pp. 273-282
	C20	Jeffrey W. Millard et al., "Solubilization by cosolvents Establishing useful constants for the log-linear model," Int'l Journal of Pharmaceutics Vol. 245, 2002, pp. 153-166
	C21	C. Baumgarten et al., "Initial Treatment of Symptomatic Mild to Moderate Bronchial Asthma with the Salmeterol/Fluticasone Propionate (50/250µg) Combination Product (SAS 40023)" European Journal of Medical Research 2002, Vol. 7, pp. 1-7
	C22	Stephen J. Fowler et al., "Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone" J. Allergy Clin. Immunol., Vol. 109, No. 6, June 2002, pp. 929-935
	C23	Elizabeth F. Juniper et al., "Impact of Inhaled Salmeterol/Fluticasone Propionate Combination Product versus Budesonide on the Health-Related Quality of Life of Patients with Asthma," Am. J. Respir. Med., Vol. 1, No. 6, 2002, pp. 435-440
	C24	William Busse et al., "Steroid-sparing effects of fluticasone propionate 100 µg and salmeterol 50 µg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 µg administered twice daily" J. Allergy Clin. Immunol., Vol. 111, No. 1, January 2003, pp. 57-65
	C25	UENO H ET AL, "SYNTHESIS AND EVALUATION OF ANTIINFLAMMATORY ACTIVITIES OF A SERIES OF CORTICOSTEROID 17. ALPHA -ESTERS CONTAINING A FUNCTIONAL GROUP", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, Vol. 34, No. 8, August 1991, pp. 2468-2473
	C26	PETER J BARNES, "Novel approaches and targets for treatment of Chronic Obstructive Pulmonary Disease" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 160, 1999, pp. S72-S79
	C27	B.J O CONNER: "Combination Therapy", PULMONARY PHARMACOLOGY AND THERAPEUTICS, Vol.11, No. 5/6, 1998, pp. 397 - 399
BB	C28	PETER J BARNES, "Chronic Obstructive Pulmonary Disease: new opportunities for drug development" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, Vol. 19, No.10, 1998, pp. 415 - 423
Continued on page 6		

EXAMINER <i>Radio</i>	DATE CONSIDERED 1/12/04
------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: PG4734		SERIAL NO.: 10/066,951	
				APPLICANT: BIGGADIKE, et. al.			
				FILING DATE: 02/04/2002		GROUP 1616	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continued on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
Continued on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
BB	C29	SIMON BOWLER, "Long acting beta agonists", AUSTRALIAN FAMILY PHYSICIAN, Vol 27, No. 12, 1998, pp. 1114-1118					
	C30	NAEDLE-RISHA R ET AL, "Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long acting beta-agonists with inhaled corticosteroids", THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, Vol 101, No. 9, September 2001, pp.2001-09					
	C31	T VAN DER MOLEN ET AL, "EFFECTS OF THE LONG ACTING BETA AGONIST FORMOTEROL ON ASTHMA CONTROL IN ASTHMATIC PATIENTS USING INHALED CORTICOSTEROIDS", Vol. 52, No. 6, 1997, pp. 535-539					
	C32	B.N. LUTSKY et al, "A Novel Class of potent Topical Anti-inflammatory Agents: 17 Benzoylated, 7 - Halogeno Substituted Corticosteroids", Arzneimittel Forschung, Vol. 29, No. 11, Nov. 1979, pp. 1662-1667					
	C33	PETER J. BARNES, "Efficacy of Inhaled Corticosteroids in Asthma", The Journal of Allergy and Clinical Immunology, Vol. 102, No. 4, pp. 531-538, 1998.					
	C34	US Publication No. 2002/0081266 publ. on 06/27/02					
	C35	US Publication No. 2002/0103392 publ. on 08/01/02					
	C36	US Publication No. 2002/0173496 publ. on 11/21/02					
	C37	US Publication No. 2003/0073676 publ. on 04/17/03					
	C38	US Publication No. 2003/0109511 publ. on 06/12/03					
	C39	US Publication No. 2003/0144257 publ. on 07/31/03					
BB	C40	US Publication No. 2003/0158163 publ. on 08/21/03					
Continued on page							
EXAMINER <i>Padio</i>					DATE CONSIDERED 1/12/04		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							